Medizinische Universität Graz - Research portal

Go directly to the nagivation.
Go directly to the content.

Navigation/Search

Selected Publication:

Fritsch, G; Urban, C.
Transient encephalopathy during the late course of treatment with high-dose methotrexate.
Cancer. 1984; 53(9):1849-1851 Doi: 10.1002/1097-0142(19840501)53:9<1849::AID-CNCR2820530909>3.0.CO;2-6 (- Case Report)
Web of Science PubMed FullText FullText_MUG Google Scholar

Co-authors Med Uni Graz: Urban Ernst-Christian
Altmetrics:
Dimensions Citations:
Plum Analytics:
Scite (citation analytics):
Abstract:: An acute episode of encephalopathy after the infusion of 16 g methotrexate is reported in a 12-year-old girl with osteogenic sarcoma. The complication occurred during the 11th treatment course, when severe vomiting and diarrhea were followed by a low urine output with consecutive toxic concentrations of methotrexate in serum and cerebrospinal fluid leading to severe systemic and central nervous system toxicity. The onset of the central nervous system toxicity was acute with slurred speech, paresis of the external rectus eye muscles, ataxia, and hemiparesis, and symptoms resolved completely after 30 hours by treatment with calcium leucovorin and forced diuresis. After management of the cerebral and systemic toxicity, high-dose methotrexate treatment could be reinstituted, and was followed by no further complications. In contrast to the transient cerebral dysfunctions, probably caused by embolization of tumor tissue in the early course of high-dose methotrexate treatment, the acute neurologic syndrome observed in the current case after the prolonged use of methotrexate seemed to be related to direct central nervous system toxicity of the drug.
Find related publications in this database (using NLM MeSH Indexing): Bone Neoplasms - drug therapy; Brain Diseases - chemically induced; Child - chemically induced; Female - chemically induced; Humans - chemically induced; Humerus - chemically induced; Lung Neoplasms - drug therapy; Methotrexate - administration and dosage; Osteosarcoma - drug therapy; Time Factors - drug therapy; Tomography, X-Ray Computed - drug therapy